GtoPdb is requesting financial support from commercial users. Please see our sustainability page for more information.
| No information available. |
Summary of Clinical Use  |
| First approval was granted by China's NMPA in 2025, to treat recurrent ovarian, fallopian tube, or primary peritoneal cancers in combination with paclitaxel, liposomal doxorubicin, or topotecan. |
| Clinical Trials | |||||
| Clinical Trial ID | Title | Type | Source | Comment | References |
| NCT04908787 | A Phase III Study of BD0801 Combined With Chemotherapy in Recurrent, Platinum-resistant Epithelial Ovarian Cancer | Phase 3 Interventional | Jiangsu Simcere Pharmaceutical Co., Ltd. | 1 | |
